Human dendritic cells mediate anti-tumor activity against hematopoietic tumor cells without direct contact and Fas/FasL killing pathway

Oncology Reports

Volumn 11, Issue 5, 2004, Pages 1017-1023

  Ayres, Flávio Monteiro ^a   Narita, Miwako ^b   Takahashi, Masuhiro ^b   Yano, Toshio ^a   Liu, Aichun ^a   Toba, Ken ^a   Furukawa, Tatsuo ^a   Aizawa, Yoshifusa ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Dendritic cells; Fas FasL; Hematopoietic tumor; Tumor immunity

Indexed keywords

FAS ANTIGEN; FAS LIGAND; FAS PROTEIN, HUMAN; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; MESSENGER RNA; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; BLOOD DISEASE; CELL DIVISION; COCULTURE; DENDRITIC CELL; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIGENS, CD95; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DENDRITIC CELLS; FAS LIGAND PROTEIN; HEMATOLOGIC NEOPLASMS; HUMANS; MEMBRANE GLYCOPROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 15844418040     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.5.1017     Document Type: Article

References (28)

1. Banchereau J and Steinman R: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998.
2. Quah B and O'Neill HC: Review: the application of dendritic cell-derived exosomes in tumour immunotherapy. Cancer Biother Radiopharm 15: 185-194, 2000.
3. Amigorena S: Anti-tumor immunotherapy using dendritic-cellderived exosomes. Res Immunol 149: 661-662, 1998.
4. Janjic BM, Lu G, Pimenov A, Whiteside TL, Storkus WJ and Vujanovic NL: Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J Immunol 168: 1823-1830, 2002.
5. Joo HG, Fleming TP, Tanaka Y, Dunn TJ, Linehan DC, Goedegebuure PS and Eberlein TJ: Human dendritic cells induce tumor-specific apoptosis by soluble factors. Int J Cancer 102: 20-28, 2002.
6. Fanger NA, Maliszewski CR, Schooley K and Griffith TS: Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 190: 1155-1164, 1999.
7. 2, Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 168:1831-1839,2002.
8. Shibaki A and Katz SI: Activation through CD40 ligation induces functional Fas ligand expression by Langerhans cells. Eur J Immunol 31: 3006-3015, 2001.
9. Mullauer L, Gruber P, Sebinger D, Buch J, Wohlfart S and Chott A: Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res 488: 211-231, 2001.
10. Chernysheva AD, Kirou KA and Crow MK: T cell proliferation induced by autologous non-T cells is a response to apoptotic cells processed by dendritic cells. J Immunol 169: 1241-1250, 2002.
11. Jäger E, Jäger D and Knuth A: Clinical cancer vaccine trials. Curr Opin Immunol 14: 178-182,2002.
12. Bordignon C, Carlo-Stella C, Colombo MP, de Vincentiis A, Lanata L, Lemoli RM, Locatelli F, Olivieri A, Rondelli D, Zanon P and Tura S: Cell therapy: achievements and perspectives. Haematologica 84: 1110-1149, 1999.
13. Bohm C, Hanski ML and Gratchev A: A modification of the JAM test is necessary for a correct determination of apoptosis induced by FasL + adherent tumor cells. J Immunol Methods 217:71-78, 1998.
14. Moschella F, Maffei A, Catanzaro RP, Papadopoulos KP, Skerrett D, Hesdorffer CS and Harris PE: Transcript profiling of human dendritic cells maturation induced under defined culture conditions: comparison of the effects of tumour necrosis factor alpha, soluble CD40 ligand trimer and interferon gamma. Br J Haematol 114: 444-457, 2001.
15. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D and Schuler G: Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196: 137-151, 1996.
16. Liu S, Yu Y, Zhang M, Wang W and Cao X: The involvement of TNF-α-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-β-stimulated human dendritic cells to tumor cells. J Immunol 166: 5407-5415, 2001.
17. 51Cr-release assay to assess the cytotoxicity of dendritic cells on hematopoietic tumor cells. Immunol Invest 32: 219-228, 2003.
18. L. Cancer Immunol Immunother 51: 139-144, 2002.
19. Chapoval AI, Tamada K and Chen L: In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood 95: 2346-2351, 2000.
20. Berger CL, Hanlon D, Kanada D, Dhodapkar M, Lombilo V, Wang N, Christensen I, Howe G, Crouch J, El-Fishawy P and Edelson R: The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 99: 2929-2939, 2002.
21. Thurnher M, Zelle-Rieser C, Ramoner R, Bartsch G and Holt L: The disabled dendritic cell. FASEB J 15: 1054-1061, 2001.
22. Matzinger P: The JAM test: a simple assay for DNA fragmentation and cell death. J Immunol Methods 145: 185-192, 1991.
23. Atarashi Y, Kanaya H and Whiteside TL: A modified JAM assay detects apoptosis induced in activated lymphocytes by FasL+ human adherent tumor cells. J Immunol Methods 233: 179-182, 2000.
24. Vanderheyde N, Aksoy E, Amraoui Z, Vandenabeele P, Goldman M and Willems F: Tumoricidal activity of monocyte-derived dendritic cells: evidence for a caspase-8-dependent, Fas-associated death domain-independent mechanism. J Immunol 167:3565-3569,2001.
25. Yu Y, Hagihara M, Ando K, Gansuvd B, Matsuzawa H, Tsuchiya T, Ueda Y, Inoue H, Hotta T and Kato S: Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells. J Immunol 166: 1590-1600, 2001.
26. Hubert P, Giannini SL, Vanderplasschen A, Franzen-Detrooz E, Jacobs N, Boniver J and Delvenne P: Dendritic cells induce the death of human papillomavirus-transformed keratinocytes. FASEB J 15: 2521-2523, 2001.
27. Vidalain PO, Azocar O, Yagita H, Rabourdin-Combe C and Servet-Delprat C: Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand. J Immunol 167: 3765-3772, 2001.
28. 1 phase of the cell cycle and can be increased by interferon treatment. Leukemia 17: 576-584, 2003.